In the cerebellum, mutations that enhance HH signaling are oncogenic, driving the formation of human medulloblastomas, both sporadic and syndromic [7], and murine medulloblastomas in transgenic Ptc+/− and SmoA1 mice [8], [9]. The gene discussed is RET; the disease is medulloblastoma.